Recent
Reports | Background Articles | Outcome
Data
Recent
Reports
-
Chemokine-idiotype fusion DNA vaccines are potentiated by
bivalency and xenogeneic sequences
The results suggest that bivalency and foreign sequences combine
to increase the efficiency of chemokine-Id DNA vaccines.
Phase I Trial of a Novel Intradermal Idiotype Vaccine in
Patients with Advanced B-Cell Lymphoma: Specific Immune Responses
Despite Profound Immunosuppression cancerres.aacrjournals.org
Of 17 evaluable patients, five developed specific
anti-vaccine antibodies, and eight developed anti-Fab T-cell
responses. T-cell reactivity was independent of the cellular immune
status and was idiotype specific as shown by statistical regression
analysis (P = 0.0024) and epitope mapping studies. Intradermal
administration of uncoupled recombinant idiotype with
appropriate adjuvants may overcome profound clinical immunosuppression
and induce specific immune responses.
A novel proteoliposomal vaccine induces antitumor immunity
against
follicular lymphoma - bloodjournal.hematology
Membrane-proteoliposome structures (MPs) are useful in preparing
patient-specific vaccines against specific white blood cell (WBC)
malignancies. The inventive MPs typically contain a membrane component
derived from a specific WBC. Other useful components include
immunostimulators and exogenous lipids. The resulting vaccines are
both patient- and malignancy-specific. ~ Patent
information pharmcast.com
-
Custom-Made Lymphoma Vaccine
Promising - webmd.com
9-2006
Vaccine Made From Patient's Own Tumor Cells Teaches Immune System
to Fight Cancer
-
FDA Gives Permission to Use Very Sensitive Molecular Evidence
of
Cancer in BiovaxID Pivotal Phase 3 Clinical Trial - biz.yahoo.com
-
In vivo disruption of tolerogenic [tolerance producing]
cross-presentation mechanisms uncovers an effective T-cell
activation by B-cell lymphomas leading to antitumor immunity. Blood.
2006 Apr 1;107(7):2871-8. Epub 2005 Dec 8. PMID: 16339406
| Related
articles
BiovaxID™ Vaccine Therapy of Follicular
Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial
and Status of a Controlled, Randomized Phase III Trial. Session Type: Poster
Session 645-II
Amplification of tumor-specific regulatory T cells
following therapeutic cancer vaccines.
Blood. 2006 Jan 15;107(2):628-36. Epub 2005 Sep 22. PMID:
16179369 | Related
articles
Favrille Completes FavId
Enrollment - thestreet.com
BiovaxID™ Promising for Follicular Lymphoma - cancerconsultants.com
For patients who were in remission following PACE chemotherapy after 6
months and received BiovaxID vaccine: At a median follow-up of 9.2
years - 45% of patients remained in remission, overall survival
rate is 95%. The median cancer-free survival was 8 years.
Therapeutic vaccination against murine lymphoma by
intratumoral injection of naive dendritic cells.
Cancer Res. 2005 Jul 1;65(13):5958-64. PMID:
15994975 | Related
articles
Recombinant, tumour-derived idiotype vaccination
for indolent B cell non-Hodgkin's lymphomas: a focus on FavId.
Expert Opin Biol Ther. 2005 Jun;5(6):841-52. PMID:
15952914 | Related
articles
Vaccine Therapy for Non-Hodgkin's Lymphoma: An Interview With Joseph M. Connors, MD
Hematology-Oncology 7(1), 2004. © 2004 Medscape (free login req.) 01/09/2004
Idiotype Vaccine Following EPOCH-Rituximab
Treatment in Untreated Mantle Cell Lymphoma. Wyndham H. Wilson, et al
Center for Cancer Research, National Cancer Institute, Bethesda, MD,
USA
- abstracts-on-line.com
Feasibility of idiotype vaccination was statistically compared among five different B-cell malignancies in first relapse. When based on hybridoma production techniques, idiotypic vaccination for relapsed B-cell malignancies was consistently feasible only in follicular lymphoma patients, whereas the main cause of failure in other settings was the short survival of idiotype-producing
hybridomas. - haematologica.it
ASCO 2003 - Oncophage (for indolent fNHL) in
the Phase II trial, there were responses observed ... suggesting
the potential utility of the vaccine in patients with minimal residual
disease. BusWire
Anti-idiotypic vaccination in the treatment of low-grade B-cell
lymphoma - Haematologica 2002 Apr;87(4):400-7 abstract
- NIH.gov
Biovest
Cancer Vaccine -- Overview of Vaccine Results - accentia.net
CpG-DNA activates dendritic cells in vivo: T helper
cell-independent cytotoxic T cell responses to soluble proteins. Eur J
Immunol. 2000 Dec;30(12):3591-7. - PubMed
| Related
abstracts
Immunogenicity of a plasmid DNA vaccine encoding chimeric
idiotype in patients with B-cell lymphoma.
Cancer Res. 2002 Oct 15;62(20):5845-52.
PMID: 12384547 - PubMed
Vaccine Therapies for Non-Hodgkin's Lymphoma.
Current Treat Options Oncol. 2002 Aug;3(4):307-15.
PMID: 12074767 - PubMed
Background Articles
-
Anti-idiotype vaccines for human follicular lymphoma. Leukemia.
2000 Aug;14(8):1333-9.
Review. PMID: 10942225 - PubMed
Anti-idiotypic DNA vaccines for B-cell lymphoma therapy.
Front Biosci. 2002 Jan 1;7:d228-34. Review. PMID: 11779689 - PubMed
Cancer Vaccines for Hematologic Malignancies:
Ivan M. Borrello, MD, Eduardo M.
Sotomayor, MD -
Medscape Free login req.
Consequences of cell death: exposure to necrotic tumor cells,
but not primary tissue cells or apoptotic cells, induces the
maturation of immunostimulatory dendritic cells," Journal of
Experimental Medicine - PDF
| PDF-Help Summer_2002
FDA Committee on vaccine technology, study
design, etc. (posted 2/7/01) - PDF
| PDF-Help
Heat Shock Proteins vaccine - White
Paper from Antigenics
Potential: From Basic Science Breakthroughs to Feasible
Personalized Medicine
Identification of
Relevant Cancer Antigens for Vaccine Development (2/23/01) - NEJM.ORG
Idiotype vaccines for non-Hodgkin's lymphoma induce polyclonal
immune responses that cover mutated tumor idiotypes: comparison of
different vaccine formulations. Blood. 1997 Nov 1;90(9):3699-706.
PMID: 9345055 - Caspar
CB, Levy S, Levy R. | Abstracts
Immunogenicity of a plasmid DNA vaccine encoding chimeric
idiotype in patients with B-cell lymphoma.
Cancer Res. 2002 Oct 15;62(20):5845-52. PMID: 12384547 - PubMed
Immunotherapy Shows Promise for Non-Hodgkin's Lymphoma - Medscape
May_20_2002
"The goal is really to delay or prevent the need for
chemotherapy," said study author Dr. John Timmerman, an assistant
professor of medicine at the University of California, Los Angeles.
Retention of an idiotypic determinant in a human B-cell lymphoma
undergoing immunoglobulin variable-region mutation. Proc
Natl Acad Sci U S A. 1987 Jul;84(14):5053-7. PMID: 3496601
- PubMed
| Abstracts
Vaccines:
Critical role of dendritic Cells 3/18/2000 - Medscape Free login req.
Clinical Trial Outcomes & Review Articles
 TOPIC
SEARCH: PubMed
| ASCO
| Medscape
BiovaxID™ Vaccine Therapy of Follicular
Lymphoma in First Remission: Long-Term Follow-Up of a Phase II Trial
and Status of a Controlled, Randomized Phase III Trial. Session Type: Poster
Session 645-II
ASH 2003 Update: Cellular Therapies and Vaccines
for Hematologic Malignancies - CancerConsultants.com
Induction of T-cell responses by tumor antigen vaccination in
mantle cell lymphoma following rituximab-based treatment - ASCO
2003
Clinical Outcome of Lymphoma Patients After Idiotype Vaccination
Is Correlated With Humoral Immune Response and Immunoglobulin G Fc
Receptor Genotype.
J Clin Oncol. 2004 Oct 13 PMID:
15483014 |
Complete molecular remissions induced by patient-specific vaccination plus
granulocyte-monocyte colony-stimulating factor against lymphoma.
Nat Med. 1999 Oct;5(10):1171-7. PMID: 10502821
| PDF | PDF-Help
-
Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma:
clinical and immune responses in 35 patients. Blood. 2002 Mar
1;99(5):1517-26. PMID: 11861263 PubMed
Idiotype vaccination
following ABMT can stimulate specific anti-idiotype immune responses
in patients with B-cell lymphoma. Biol Blood Marrow Transplant.
2001;7(9):517-22. PMID: 11669219 - PubMed
Safety and efficacy of heat shock protein-peptide 96 complex
(HSPPC-96)
in low-grade lymphoma - ASCO
2003
Idiotypic vaccination
for B-cell malignancies as a model for therapeutic cancer vaccines:
from prototype protein to second generation vaccines. Haematologica.
2002 Sep;87(9):989-1001. PMID: 12217812
- PubMed
| Abstracts
Role of anti-idiotype vaccines in the modern treatment of human
follicular lymphoma.
Expert Rev Anticancer Ther. 2001 Jun;1(1):65-72.
Review. PMID: 12113135 - PubMed
-
Tumor-specific idiotype vaccines in the treatment of patients with
B-cell lymphoma --
long-term results of a clinical trial. Blood. 1997
May 1;89(9):3129-35.
PMID: 9129015
- Hsu
FJ, Caspar ... Levy R. | PDF
| PDF-Help | Abstracts
Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed
dendritic cells.
Nat Med. 1996 Jan;2(1):52-8. PMID: 8564842; UI: 96135165. - Hsu
FJ, et al. See
Related Articles
Vaccine Trials for the Clinician: Prospects for Tumor Antigens. Oncologist.
1997;2(5):284-299.
PMID: 10388061. - Osanto
S. See
Related Articles
|
